Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2-early breast cancer (EBC): A correlation analysis.

被引：0
|
作者：
Untch, Michael
Perol, David
Mayer, Erica L.
Cortes, Javier
Nusch, Arnd
Cameron, David A.
Barrios, Carlos
Delea, Thomas E.
Salas, Tonatiuh Romero
Kalra, Manik
Gupta, Rhea
Pathak, Purnima
Fasching, Peter A.
机构：
[1] Helios Klinikum Berlin Buch, Interdisciplinary Breast Canc Ctr, Berlin, Germany
[2] Ctr Leon Berard, Dept Clin Res, Lyon, France
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Int Breast Canc Ctr, Quiron Grp, Barcelona, Spain
[5] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[7] Policy Anal Inc, Chestnut Hill, MA USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Healthcare Pvt Ltd, Hyderabad, India
[10] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2-early breast cancer (EBC) patients.
    Jimenez Rodriguez, Begona
    Lavado Fernandez, Ana Isabel
    Ribelles, Nuria
    Sanchez-Rovira, Pedro
    Vicioso, Luis
    Alvarez, Martina
    de Luque, Vanessa
    Ramirez Tortosa, Cesar
    Buckingham, Wesley
    Schaper, Carl
    Jeiranian, Arthur
    Dowidar, Naeem
    Ferree, Sean
    Villar, Ester
    Zarcos, Irene
    Sanchez-Munoz, Alfonso
    Gonzalez-Hermoso, Carlos
    Llacer Perez, Casilda
    Prat, Aleix
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
    Oba, Koji
    Paoletti, Xavier
    Alberts, Steven
    Bang, Yung-Jue
    Benedetti, Jacqueline
    Bleiberg, Harry
    Catalano, Paul
    Lordick, Florian
    Michiels, Stefan
    Morita, Satoshi
    Ohashi, Yasuo
    Pignon, Jean-pierre
    Rougier, Philippe
    Sasako, Mitsuru
    Sakamoto, Junichi
    Sargent, Daniel
    Shitara, Kohei
    Cutsem, Eric Van
    Buyse, Marc
    Burzykowski, Tomasz
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1600 - 1607
  • [43] Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data.
    Ajani, Jaffer A.
    Leung, Lisa
    Kanters, Steve
    Singh, Prianka
    Kurt, Murat
    Kim, Inkyu
    Pourrahmat, Mir-Masoud
    Friedman, Howard S.
    Navaratnam, Prakash
    Reardon, Gregory
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 321 - 321
  • [44] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [45] Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7
    De Laurentiis, M.
    Merino, L. de la Cruz
    Hart, L.
    Bardia, A.
    Im, S-A.
    Sohn, J.
    Neven, P.
    Martin, M.
    Ji, Y.
    Yang, S.
    Hu, H.
    Lteif, A.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S378 - S379
  • [46] Predictive value of multigene assay for chemotherapy benefit in patients with HR+/HER2-early breast cancer
    Kwon, Mi Jeong
    CANCER RESEARCH, 2018, 78 (13)
  • [47] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. C.
    Sanchez, L. M. Manso
    Paluch-Shimon, S.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1384
  • [48] Health-Related Quality of Life Among Patients With HR+/HER2-Early Breast Cancer
    Criscitiello, Carmen
    Spurden, Dean
    Piercy, James
    Rider, Alex
    Williams, Rhys
    Mitra, Debanjali
    Wild, Rosie
    Corsaro, Massimo
    Kurosky, Samantha K.
    Law, Ernest H.
    CLINICAL THERAPEUTICS, 2021, 43 (07) : 1228 - +
  • [49] Correlation analysis to assess surrogate endpoints for overall survival (OS) in triplenegative breast cancer (TNBC)
    Perez-Granado, Judith
    Kalucha, Ankit
    Gala, Kinisha
    Bodriagova, Olga
    Vidal, Laura
    Larvol, Bruno
    Gramling, Mark
    Saini, Kamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Prognostic variables for risk of recurrence in patients (pts) with HR+/HER2-early breast cancer (EBC) using data from the NATALEE trial: a machine learning (ML) model-based analysis
    Fasching, P. A.
    Barrios, C. H.
    Lim, E.
    Graff, S. L.
    Chia, S.
    Frenel, J. -s.
    Im, S. -a.
    Huang, C. -s.
    Ring, A.
    Nowecki, Z.
    Liu, Q.
    Akdere, M.
    Zarate, J. P.
    Hu, H.
    Pantoja, K.
    O'Shaughnessy, J. A.
    BREAST, 2025, 80
12345